PAP-α Activators
PAP-α activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of PAP-α through modulation of various cellular signaling pathways. For instance, Bisindolylmaleimide I, a selective inhibitor of PKC, and Staurosporine, a broad-spectrum kinase inhibitor, function by reducing the phosphorylation of downstream targets, thus alleviating inhibitory phosphorylation that might suppress pathways relevant to PAP-α's activity. Similarly, the use of kinase inhibitors such as LY294002, U0126, SB203580, and Wortmannin modifies the signaling landscape, enhancing PAP-α activity by shifting the cellular balance away from competitive or inhibitory signaling pathways. This shift is crucial as it creates an environment where PAP-α can function more effectively. Furthermore, compounds like Dibutyryl-cAMP and Forskolin, which elevate cAMP levels and subsequently activate PKA, lead to the phosphorylation of substrates that interact with or regulate PAP-α, thus indirectly promoting its activity. Additionally, the modulation of intracellular calcium levels by agents such as Ionomycin and Thapsigargin also plays a significant role in enhancing PAP-α activity. These agents increase calcium concentrations, thereby activating calcium-dependent signaling pathways that influence the cellular context within which PAP-α operates.
The functional modulation of PAP-α is further influenced by compounds that target various kinase pathways. Epigallocatechin Gallate (EGCG), with its ability to inhibit multiple kinases, alters cellular signaling dynamics, potentially reducing the phosphorylation of proteins that may act as negative regulators of PAP-α's pathways. Genistein, through its inhibition of tyrosine kinase activity, enhances PAP-α activity by reducing competitive phosphorylation events. The collective action of these compounds, through their targeted effects on cellular signaling, facilitates the enhancement of PAP-α-mediated functions. This diverse yet specific modulation of intracellular pathways and signaling environments underscores the complex regulatory mechanisms that can be leveraged to enhance the activity of PAP-α, emphasizing the intricate interplay between various biochemical pathways and PAP-α's functional role within these networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A potent and selective inhibitor of Protein Kinase C (PKC). Inhibition of PKC leads to a reduction in the phosphorylation of downstream targets, which can indirectly enhance the activity of PAP-α by alleviating the inhibitory phosphorylation that PKC imposes on pathways relevant to PAP-α's function. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
A cAMP analog that activates Protein Kinase A (PKA). PKA can phosphorylate several substrates that interact with or regulate PAP-α, leading to an indirect enhancement of PAP-α activity through the modulation of these interacting proteins. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore that increases intracellular calcium concentrations. Elevated calcium can activate various calcium-dependent enzymes and signaling pathways, indirectly influencing PAP-α activity by modifying the cellular environment in which PAP-α operates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
An inhibitor of the PI3K/Akt pathway. By inhibiting this pathway, there is a shift in the cellular signaling balance, which can indirectly enhance PAP-α activity, as PAP-α might be more active in a cellular context with reduced PI3K/Akt signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
An inhibitor of p38 MAPK. By inhibiting p38 MAPK, it alters the cellular signaling environment, potentially enhancing PAP-α’s activity by reducing the inhibitory effects of the p38 MAPK pathway on processes in which PAP-α is involved. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase, leading to increased cAMP levels and subsequent activation of PKA. PKA can modulate various substrates and signaling pathways, indirectly enhancing PAP-α activity through these alterations. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A SERCA pump inhibitor, leading to increased cytosolic calcium levels. This elevation in calcium can indirectly enhance PAP-α activity by activating calcium-dependent signaling pathways and enzymes that may interact with or modulate PAP-α function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Known for its inhibition of various kinases. This broad kinase inhibition can shift cellular signaling dynamics, potentially enhancing PAP-α activity by reducing the phosphorylation of proteins that may act as negative regulators or competitors of PAP-α’s pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A broad-spectrum kinase inhibitor. While it affects multiple kinases, this broad inhibition can indirectly enhance PAP-α activity by reducing the phosphorylation of inhibitory proteins or pathways that negatively impact PAP-α’s function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
An inhibitor of PI3K. By inhibiting PI3K, it can lead to a reduction in Akt pathway signaling, potentially enhancing PAP-α activity by modifying the signaling environment to favor pathways in which PAP-α is more active. | ||||||